164 related articles for article (PubMed ID: 31409895)
1. Epigenetic inactivation of the splicing RNA-binding protein CELF2 in human breast cancer.
Piqué L; Martinez de Paz A; Piñeyro D; Martínez-Cardús A; Castro de Moura M; Llinàs-Arias P; Setien F; Gomez-Miragaya J; Gonzalez-Suarez E; Sigurdsson S; Jonasson JG; Villanueva A; Vidal A; Davalos V; Esteller M
Oncogene; 2019 Nov; 38(45):7106-7112. PubMed ID: 31409895
[TBL] [Abstract][Full Text] [Related]
2. Reciprocal regulation of hnRNP C and CELF2 through translation and transcription tunes splicing activity in T cells.
Mallory MJ; McClory SP; Chatrikhi R; Gazzara MR; Ontiveros RJ; Lynch KW
Nucleic Acids Res; 2020 Jun; 48(10):5710-5719. PubMed ID: 32338744
[TBL] [Abstract][Full Text] [Related]
3. Pleotropic role of RNA binding protein CELF2 in autophagy induction.
New J; Subramaniam D; Ramalingam S; Enders J; Sayed AAA; Ponnurangam S; Standing D; Ramamoorthy P; O'Neil M; Dixon DA; Saha S; Umar S; Gunewardena S; Jensen RA; Thomas SM; Anant S
Mol Carcinog; 2019 Aug; 58(8):1400-1409. PubMed ID: 31020708
[TBL] [Abstract][Full Text] [Related]
4. Antagonistic regulation of mRNA expression and splicing by CELF and MBNL proteins.
Wang ET; Ward AJ; Cherone JM; Giudice J; Wang TT; Treacy DJ; Lambert NJ; Freese P; Saxena T; Cooper TA; Burge CB
Genome Res; 2015 Jun; 25(6):858-71. PubMed ID: 25883322
[TBL] [Abstract][Full Text] [Related]
5. RNA Binding Protein CELF2 Regulates Signal-Induced Alternative Polyadenylation by Competing with Enhancers of the Polyadenylation Machinery.
Chatrikhi R; Mallory MJ; Gazzara MR; Agosto LM; Zhu WS; Litterman AJ; Ansel KM; Lynch KW
Cell Rep; 2019 Sep; 28(11):2795-2806.e3. PubMed ID: 31509743
[TBL] [Abstract][Full Text] [Related]
6. Position-dependent activity of CELF2 in the regulation of splicing and implications for signal-responsive regulation in T cells.
Ajith S; Gazzara MR; Cole BS; Shankarling G; Martinez NM; Mallory MJ; Lynch KW
RNA Biol; 2016 Jun; 13(6):569-81. PubMed ID: 27096301
[TBL] [Abstract][Full Text] [Related]
7. CELF2 suppresses non-small cell lung carcinoma growth by inhibiting the PREX2-PTEN interaction.
Yeung YT; Fan S; Lu B; Yin S; Yang S; Nie W; Wang M; Zhou L; Li T; Li X; Bode AM; Dong Z
Carcinogenesis; 2020 May; 41(3):377-389. PubMed ID: 31241130
[TBL] [Abstract][Full Text] [Related]
8. LncRNA RHPN1-AS1 promotes the progression of nasopharyngeal carcinoma by targeting CELF2 expression.
Zhao Y; Zhou H; Dong W
Exp Mol Pathol; 2021 Oct; 122():104671. PubMed ID: 34358519
[TBL] [Abstract][Full Text] [Related]
9. CELF2 is a candidate prognostic and immunotherapy biomarker in triple-negative breast cancer and lung squamous cell carcinoma: A pan-cancer analysis.
Wang L; Liu Z; Liu L; Guo C; Jiao D; Li L; Zhao J; Han X; Sun Y
J Cell Mol Med; 2021 Aug; 25(15):7559-7574. PubMed ID: 34288370
[TBL] [Abstract][Full Text] [Related]
10. CELF2 regulates the species-specific alternative splicing of TREM2.
Yanaizu M; Washizu C; Nukina N; Satoh JI; Kino Y
Sci Rep; 2020 Oct; 10(1):17995. PubMed ID: 33093587
[TBL] [Abstract][Full Text] [Related]
11. miR-615-3p promotes proliferation and migration and inhibits apoptosis through its potential target CELF2 in gastric cancer.
Wang J; Liu L; Sun Y; Xue Y; Qu J; Pan S; Li H; Qu H; Wang J; Zhang J
Biomed Pharmacother; 2018 May; 101():406-413. PubMed ID: 29501762
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of miR-95-3p inhibits proliferation, and invasion promoting apoptosis of glioma cells by targeting CELF2.
Fan B; Jiao BH; Fan FS; Lu SK; Song J; Guo CY; Yang JK; Yang L
Int J Oncol; 2015 Sep; 47(3):1025-33. PubMed ID: 26165303
[TBL] [Abstract][Full Text] [Related]
13. Induced transcription and stability of CELF2 mRNA drives widespread alternative splicing during T-cell signaling.
Mallory MJ; Allon SJ; Qiu J; Gazzara MR; Tapescu I; Martinez NM; Fu XD; Lynch KW
Proc Natl Acad Sci U S A; 2015 Apr; 112(17):E2139-48. PubMed ID: 25870297
[TBL] [Abstract][Full Text] [Related]
14. Mis-splicing of Tau exon 10 in myotonic dystrophy type 1 is reproduced by overexpression of CELF2 but not by MBNL1 silencing.
Dhaenens CM; Tran H; Frandemiche ML; Carpentier C; Schraen-Maschke S; Sistiaga A; Goicoechea M; Eddarkaoui S; Van Brussels E; Obriot H; Labudeck A; Gevaert MH; Fernandez-Gomez F; Charlet-Berguerand N; Deramecourt V; Maurage CA; Buée L; Lopez de Munain A; Sablonnière B; Caillet-Boudin ML; Sergeant N
Biochim Biophys Acta; 2011 Jul; 1812(7):732-42. PubMed ID: 21439371
[TBL] [Abstract][Full Text] [Related]
15. An integrated genomics analysis of epigenetic subtypes in human breast tumors links DNA methylation patterns to chromatin states in normal mammary cells.
Holm K; Staaf J; Lauss M; Aine M; Lindgren D; Bendahl PO; Vallon-Christersson J; Barkardottir RB; Höglund M; Borg Å; Jönsson G; Ringnér M
Breast Cancer Res; 2016 Feb; 18(1):27. PubMed ID: 26923702
[TBL] [Abstract][Full Text] [Related]
16. Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer.
Ai L; Tao Q; Zhong S; Fields CR; Kim WJ; Lee MW; Cui Y; Brown KD; Robertson KD
Carcinogenesis; 2006 Jul; 27(7):1341-8. PubMed ID: 16501252
[TBL] [Abstract][Full Text] [Related]
17. miR-363-3p induces EMT via the Wnt/β-catenin pathway in glioma cells by targeting CELF2.
Fan B; Su B; Song G; Liu X; Yan Z; Wang S; Hu F; Yang J
J Cell Mol Med; 2021 Nov; 25(22):10418-10429. PubMed ID: 34636136
[TBL] [Abstract][Full Text] [Related]
18. Pattern of expression of genes linked to epigenetic silencing in human breast cancer.
Munot K; Bell SM; Lane S; Horgan K; Hanby AM; Speirs V
Hum Pathol; 2006 Aug; 37(8):989-99. PubMed ID: 16867861
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic modifications of splicing factor genes in myelodysplastic syndromes and acute myeloid leukemia.
Wong JJ; Lau KA; Pinello N; Rasko JE
Cancer Sci; 2014 Nov; 105(11):1457-63. PubMed ID: 25220401
[TBL] [Abstract][Full Text] [Related]
20. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
Veeck J; Noetzel E; Bektas N; Jost E; Hartmann A; Knüchel R; Dahl E
Mol Cancer; 2008 Nov; 7():83. PubMed ID: 18990230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
